Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen

Q32 Bio has acquired control of the development and commercialization rights to the anti-IL-7Rα antibody bempikibart. Currently being evaluated in two Phase 2 trials for atopic dermatitis and alopecia areata, this reacquisition will bolster Q32 Bio’s autoimmune product portfolio. In 2022, Q32 Bio and Horizon Therapeutics collaborated to develop bempikibart, with plans for Horizon to acquire the program. However, after Amgen’s acquisition of Horizon, Q32 Bio regained Horizon’s rights to the antibody.